Ada Wilner Rephaeli
Ada Wilner Rephaeli
Verified email at
Cited by
Cited by
Doxorubicin-DNA adducts induce a non-topoisomerase II–mediated form of cell death
LP Swift, A Rephaeli, A Nudelman, DR Phillips, SM Cutts
Cancer research 66 (9), 4863-4871, 2006
The power and potential of doxorubicin‐DNA adducts
SM Cutts, A Nudelman, A Rephaeli, DR Phillips
IUBMB life 57 (2), 73-81, 2005
The effect of membrane potential on the mammalian sodium‐potassium pump reconstituted into phospholipid vesicles.
R Goldshlegger, SJ Karlish, A Rephaeli, WD Stein
The Journal of Physiology 387 (1), 331-355, 1987
Novel anticancer prodrugs of butyric acid. 2
A Nudelman, M Ruse, A Aviram, E Rabizadeh, M Shaklai, Y Zimrah, ...
Journal of medicinal chemistry 35 (4), 687-694, 1992
Derivatives of butyric acid as potential anti‐neoplastic agents
A Rephaeli, E Rabizadeh, A Aviram, M Shaklai, M Ruse, A Nudelman
International journal of cancer 49 (1), 66-72, 1991
The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines
A Batova, L Shao, MB Diccianni, ALYT Tanaka, A Rephaeli, A Nudelman, ...
Blood, The Journal of the American Society of Hematology 100 (9), 3319-3324, 2002
Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas
M Entin-Meer, A Rephaeli, X Yang, A Nudelman, SR VandenBerg, ...
Molecular cancer therapeutics 4 (12), 1952-1961, 2005
Prodrugs of butyric acid from bench to bedside: synthetic design, mechanisms of action, and clinical applications
A Rephaeli, R Zhuk, A Nudelman
Drug Development Research 50 (3‐4), 379-391, 2000
Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9)
SM Cutts, A Rephaeli, A Nudelman, I Hmelnitsky, DR Phillips
Cancer research 61 (22), 8194-8202, 2001
Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation
RA Forrest, LP Swift, A Rephaeli, A Nudelman, KI Kimura, DR Phillips, ...
Biochemical pharmacology 83 (12), 1602-1612, 2012
Uses of hydroxy and ether-containing oxyalkylene esters for treating metabolic conditions
A Nudelman, A Rephaeli
US Patent 6,239,176, 2001
Conformational transitions in fluorescein-labeled (Na, K) ATPase reconstituted into phospholipid vesicles.
A Rephaeli, D Richards, SJ Karlish
Journal of Biological Chemistry 261 (14), 6248-6254, 1986
Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases
A Nudelman, E Gnizi, Y Katz, R Azulai, M Cohen-Ohana, R Zhuk, ...
European journal of medicinal chemistry 36 (1), 63-74, 2001
Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
A Rephaeli
US Patent 5,939,455, 1999
Electrical potential accelerates the E1P (Na)----E2P conformational transition of (Na, K)-ATPase in reconstituted vesicles.
A Rephaeli, DE Richards, SJ Karlish
Journal of Biological Chemistry 261 (27), 12437-12440, 1986
Rapid alteration of c‐myc and c‐jun expression in leukemic cells induced to differentiate by a butyric acid prodrug
E Rabizadeh, M Shaklai, A Nudelman, L Eisenbach, A Rephaeli
FEBS letters 328 (3), 225-229, 1993
The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters
A Nudelman, I Levovich, SM Cutts, DR Phillips, A Rephaeli
Journal of medicinal chemistry 48 (4), 1042-1054, 2005
Metabolically stabilized oxyalkylene esters and uses thereof
A Nudelman, A Rephaeli, E Neiss, B Loev
US Patent 6,110,955, 2000
Regulation of genes coding for enzyme constituents of the bacterial phosphotransferase system
AW Rephaeli, MH Saier Jr
Journal of bacteriology 141 (2), 658-663, 1980
Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
A Nudelman, A Rephaeli
US Patent 6,071,923, 2000
The system can't perform the operation now. Try again later.
Articles 1–20